Sisram Medical Ltd. (1696) AI Stock Analysis

• Market Cap: HK$2.22B
• Dividend Yield: 2.82%
• Average Volume (3M): 469.37K
• Price to Earnings (P/E): 13.8
• Beta (1Y): 1.27
• Revenue Growth: -3.32%
• EPS Growth: -12.94%
• Country: HK
• Employees: 1,000
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): 0.11
• Shares Outstanding: 468,343,080
• 10 Day Avg. Volume: 515,040
• 30 Day Avg. Volume: 469,367
• PEG Ratio: -0.45
• Price to Book (P/B): 0.49
• Price to Sales (P/S): 0.65
• P/FCF Ratio: 7.50
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 64 Neutral
• Price Target: HK$4.50 ▲(16.28% Upside)

Sisram Medical Ltd. has a stable financial foundation with strong profitability and low leverage, but faces challenges in revenue growth and cash flow. Technical indicators suggest potential bearish momentum, while valuation metrics indicate fair pricing with a decent dividend yield.

Positive Factors

Profitability Margins

High profitability margins indicate effective cost management and pricing power, supporting long-term financial health and competitive positioning.

Low Financial Leverage

Low leverage enhances financial stability, reducing risk and providing flexibility for future investments or downturns, supporting sustainable growth.

Cash Conversion

Efficient cash conversion supports operational sustainability, enabling reinvestment in growth opportunities and providing a buffer against financial challenges.

Negative Factors

Revenue Growth Decline

A significant decline in revenue growth can impact market share and long-term viability, necessitating strategic adjustments to regain growth momentum.

Negative Free Cash Flow Growth

Declining free cash flow growth may limit the company's ability to fund operations and investments, potentially affecting future expansion and stability.

Earnings Decline

A decline in earnings per share can signal reduced profitability and efficiency, potentially impacting investor confidence and long-term growth prospects.

Sisram Medical Ltd. Business Overview & Revenue Model

Company Description

Sisram Medical Ltd, an investment holding company, designs, develops, manufactures, and sells energy-based aesthetic medical, minimally invasive treatment systems, and non-energy based devices and cosmeceuticals in the Asia Pacific, Europe, North America, Latin America, the Middle East, and Africa. It offers products and treatments portfolio, including hair removal, skin rejuvenation, acne and acne scars, body and face contouring, pigmentation and skin resurfacing, fat grafting, dermal facial fillers, skin tissue remodelling injectables, personal care, aesthetic dentistry, trans epidermal delivery, cellulite treatment, stretch marks, vascular and pigmented lesions, hydradermabrasion, blepharoplasty-non surgical eyelid lift, liposuction, feminine health, and sexual rehabilitation. The company manufactures, distributes, and sells medical equipment. It offers its products under the Alma, Soprano, Harmony, Copulla, Foshion, Accent, and LMNT brands. Sisram Medical Ltd was incorporated in 2013 and is headquartered in Caesarea, Israel.

How the Company Makes Money

Sisram Medical generates revenue through the sale of its advanced medical devices and equipment to healthcare professionals, clinics, and aesthetic practices. The primary source of income stems from direct sales of its laser systems and technologies, which are often accompanied by consumables and accessories that are essential for their operation. Additionally, the company benefits from recurring revenue streams through service agreements, maintenance contracts, and the sale of consumable products associated with its devices. Strategic partnerships with distributors and collaborations with aesthetic practitioners further enhance its market reach and contribute to its earnings, allowing Sisram Medical to capitalize on the growing demand for aesthetic treatments worldwide.

Sisram Medical Ltd. Financial Statement Overview

Summary

Sisram Medical Ltd. demonstrates a stable financial position with strong profitability margins and low leverage. However, the significant decline in revenue growth and negative free cash flow growth are areas of concern that need to be addressed to ensure long-term sustainability.

Income Statement

Sisram Medical Ltd. shows a mixed performance in its income statement. The TTM data indicates a decline in revenue growth rate by 46.8%, which is concerning. However, the company maintains a strong gross profit margin of 62.1% and a net profit margin of 7.2%, indicating efficient cost management. The EBIT and EBITDA margins are moderate at 7.9% and 11.1%, respectively, suggesting stable operational efficiency despite revenue challenges.

Balance Sheet

The balance sheet of Sisram Medical Ltd. is relatively strong, with a low debt-to-equity ratio of 0.09, indicating low financial leverage and risk. The return on equity is modest at 4.4%, reflecting moderate profitability on shareholder investments. The equity ratio stands at 73.6%, showcasing a solid equity base relative to total assets, which enhances financial stability.

Cash Flow

The cash flow statement reveals some challenges, with a negative free cash flow growth rate of -18.6% in the TTM period. However, the company maintains a healthy free cash flow to net income ratio of 0.92, indicating good cash conversion. The operating cash flow to net income ratio is 0.35, suggesting adequate cash generation from operations relative to net income.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	345.86M	349.11M	359.29M	354.48M	294.29M	162.09M
Gross Profit	210.72M	216.68M	219.53M	202.23M	166.86M	90.30M
EBITDA	33.03M	38.91M	53.43M	58.38M	55.96M	28.19M
Net Income	20.60M	25.13M	31.50M	40.17M	31.25M	13.34M
Balance Sheet
Total Assets	633.26M	627.26M	613.50M	555.60M	530.13M	431.81M
Cash, Cash Equivalents and Short-Term Investments	62.01M	71.98M	70.60M	91.49M	157.96M	116.37M
Total Debt	46.97M	43.20M	44.68M	41.34M	41.62M	37.06M
Total Liabilities	145.56M	142.47M	143.98M	123.38M	126.51M	99.92M
Stockholders Equity	466.38M	464.03M	452.31M	430.87M	402.18M	331.89M
Cash Flow
Free Cash Flow	20.87M	30.38M	35.37M	-42.28M	29.41M	16.46M
Operating Cash Flow	24.23M	33.08M	43.94M	22.04M	32.38M	25.74M
Investing Cash Flow	-17.64M	-6.59M	-32.99M	-52.11M	-46.77M	-33.51M
Financing Cash Flow	-18.79M	-16.11M	-20.97M	-17.85M	55.78M	-12.21M

Sisram Medical Ltd. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 3.87
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1696, the sentiment is Positive. The current price of 3.87 is below the 20-day moving average (MA) of 4.26, below the 50-day MA of 4.33, and below the 200-day MA of 4.80, indicating a neutral trend. The MACD of 0.09 indicates Negative momentum. The RSI at 65.27 is Neutral, neither overbought nor oversold. The STOCH value of 81.70 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:1696.

Sisram Medical Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
1789	69 Neutral	HK$6.72B	20.99	11.24%	1.26%	25.18%	55.79%
6669	67 Neutral	HK$4.14B	36.62	7.44%	―	12.94%	212.66%
1696	64 Neutral	HK$2.22B	13.81	4.46%	2.82%	-3.32%	-12.94%
1302	57 Neutral	HK$7.17B	93.26	1.98%	―	3.42%	-70.82%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
2235	44 Neutral	HK$3.15B	-103.74	-1.39%	―	49.86%	80.35%
9996	39 Underperform	HK$4.43B	-18.06	-11.20%	―	29.25%	9.02%

Sisram Medical Ltd. Corporate Events

Sisram Medical Announces Leadership Restructuring for 2026

Sisram Medical Ltd has announced significant changes in its leadership structure, effective from January 1, 2026. Mr. Yi Liu will transition from Chairman to a non-executive Director, while Mr. Lior Moshe Dayan will become the new Chairman. Mr. Eyal Ben David will take over as Chief Executive Officer, with Mr. Jiahong Li appointed as Co-Chief Executive Officer. These changes are part of a strategic realignment within the company, aiming to enhance its operational efficiency and strengthen its market position.

The most recent analyst rating on (HK:1696) stock is a Hold with a HK$4.50 price target. To see the full list of analyst forecasts on Sisram Medical Ltd. stock, see the HK:1696 Stock Forecast page.

Sisram Medical Ltd Announces New Board of Directors for 2026

Sisram Medical Ltd has announced the composition of its board of directors effective from January 1, 2026. The board includes a mix of executive, non-executive, and independent non-executive directors, with Mr. Lior Moshe Dayan serving as Chairman. This announcement is significant for stakeholders as it outlines the leadership structure that will guide the company’s strategic direction and governance.

The most recent analyst rating on (HK:1696) stock is a Hold with a HK$4.50 price target. To see the full list of analyst forecasts on Sisram Medical Ltd. stock, see the HK:1696 Stock Forecast page.

Sisram Medical Reports Strong Q3 Growth and Strategic Expansion Plans

Sisram Medical Ltd announced strong market momentum in Q3 2025, driven by increased demand in China, South Korea, and Thailand. The company reported a healthy double-digit year-on-year growth in unaudited revenue, with significant orders for its Alma Harmony platform. The company plans to expand the Soprano family in APAC and Universkin sales in the U.S., while preparing for the DAXXIFY launch in China.

The most recent analyst rating on (HK:1696) stock is a Hold with a HK$5.00 price target. To see the full list of analyst forecasts on Sisram Medical Ltd. stock, see the HK:1696 Stock Forecast page.